# Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

> **NCT04618211** · PHASE2 · COMPLETED · sponsor: **Pharvaris Netherlands B.V.** · enrollment: 74 (actual)

## Conditions studied

- Hereditary Angioedema
- Hereditary Angioedema Type I
- Hereditary Angioedema Type II
- Hereditary Angioedema Types I and II
- Hereditary Angioedema Attack
- Hereditary Angioedema With C1 Esterase Inhibitor Deficiency
- Hereditary Angioedema - Type 1
- Hereditary Angioedema - Type 2
- C1 Esterase Inhibitor Deficiency
- C1 Inhibitor Deficiency

## Interventions

- **DRUG:** Deucrictibant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04618211
- **Lead sponsor:** Pharvaris Netherlands B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-03
- **Primary completion:** 2022-09-23
- **Final completion:** 2023-03-01
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04618211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04618211, "Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04618211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*